FINWIRES · TerminalLIVE
FINWIRES

Spire Healthcare Accepts GBP1 Billion Takeover Offer; Shares Gain

By
Spire Healthcare Accepts GBP1 Billion Takeover Offer; Shares Gain

Shares in Spire Healthcare Group (SPI.L) rose more than 3% on Monday morning after the healthcare company accepted a 1.03 billion-pound-sterling takeover offer from a consortium of three private equity firms over the weekend.

The consortium, comprising funds managed or advised by Toscafund Asset Management, Three Hills and Ares Management, is offering 2.50 pounds per share in cash, implying an enterprise value of 2.31 billion pounds. The offer represents a 66.2% premium to the closing share price on May 13, the last day before the possible offer announcement.

Spire Healthcare shareholders can also opt to participate in an alternative offer and exchange some or all of their shares for loan notes issued by Tulip UK Bidco, a newly formed vehicle backed by the consortium. It is capped at 28 million shares, or 8.5% of the scheme shares. Under the alternative offer, shareholders will receive 2.5 rollover securities for each Spire share exchanged.

Spire Healthcare, which operates 38 hospitals and more than 55 clinics in the UK, launched a strategic review in September 2025 to consider various options, including a potential sale of the company. Its board plans to recommend that shareholders vote in favor of the offer.

When coming up with the decision, the board considered "the ongoing challenges of delivering the company's standalone plan against a backdrop of macroeconomic volatility, cost pressures - in particular inflation, and the dynamic nature of the payor environment."

Tulip UK Bidco, which plans to delist Spire Healthcare from the London stock exchange after completing the acquisition, will also make leadership changes. Paolo Pieri, who previously worked as chief executive at private healthcare provider Circle Health Group, is set to be named chair. Spire Healthcare CEO Justin Ash will meanwhile step down and be succeeded on an interim basis by Vice Chair David Sloman, while the buyers search for a permanent CEO.

Subject to shareholder and court approvals, among other conditions, the deal is expected to close in the fourth quarter of 2026 or the first quarter of 2027.

Related Articles

Ingenia Communities Rejects Warburg Pincus' AU$1.94 Billion Takeover Bid
US Markets

Ingenia Communities Rejects Warburg Pincus' AU$1.94 Billion Takeover Bid

Ingenia Communities (ASX:INA) has rejected Walberg Pincus' unsolicited offer to take over the property group for AU$1.94 billion, saying the proposal "substantially undervalues" the company, according to a Monday filing with the Australian Securities Exchange.The conditional, non-binding proposal, which would take the property group for AU$4.75 per security, "is not in the best interests of its security holders," Ingenia said.Ingenia said it is optimistic about its strategy, underpinned by support from its land lease and holiday accommodation sectors. The company will have opportunities to grow and give long-term value to shareholders, the developer added.The proposal is subject to due diligence, regulatory approvals, and board recommendation, and is contingent on the company abandoning its proposed acquisition of residential developer Peet (ASX:PPC).In late August, Ingenia offered to purchase Peet for AU$0.68 per share and scrip consideration of 0.3367 Ingenia stapled securities per Peet share, valuing Ingenia's peer at AU$992.5 million.Shares in Ingenia surged 14% during the midday session in Sydney.

ASX:INA
Fosun Pharma Plans HK$1 Billion Share Buyback Funded by Gland Pharma Stake Sale
US Markets

Fosun Pharma Plans HK$1 Billion Share Buyback Funded by Gland Pharma Stake Sale

Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) plans to repurchase up to HK$1 billion of its H-shares over a 12-month period.The plan, which the Chinese pharmaceutical firm said was designed to address market concerns and bolster shareholder value, will be funded by a divestment in its Indian unit.Fosun's indirect subsidiary, Fosun Pharma Singapore, sold 9.897 million shares in Gland Pharma (NSE:GLAND, BOM:543245) for about 28 billion Indian rupees. The sale was executed through block trades and open-market transactions at an average price of 2,828.78 rupees each, representing a 2.72% discount to the previous close.The sale reduces Fosun International's equity stake in Gland Pharma to 45.76% from 51.76%. Gland Pharma will remain a subsidiary of Fosun Pharma and its financial results will continue to be consolidated under Fosun's umbrella.The share buyback follows an upbeat first half for Fosun Pharma. Attributable net profit jumped 19.1% year over year to 1.14 billion yuan on the back of a 4.75% increase in revenue to 20.4 billion yuan."Looking ahead, Fosun Pharma will stay focused on innovation and globalization, accelerating the R&D progress and commercialization of its major pipeline candidates," the company said.Fosun Pharma's shares jumped more than 7% in Hong Kong and over 1% in Shanghai in recent trade.

BOM:543245HKG:2196NSE:GLANDSHA:600196
Australian Job Ads Rise in August, But Poised to Trend Lower as Economic Momentum Fades
US Markets

Australian Job Ads Rise in August, But Poised to Trend Lower as Economic Momentum Fades

Labor demand in Australia remained resilient in August with a rise in the number of job advertisements, but the volume of ads is expected to trend lower over the coming months as the impact of the central bank's monetary tightening takes hold.ANZ-Indeed Australian Job Ads, a monthly indicator that tracks the total number of internet job advertisements across select websites, rose by a seasonally adjusted 2.5% month over month in August following an upwardly revised 1.9% increase in July, ANZ Research said in a Monday release.The growth was driven by notable gains across Victoria, Western Australia, and Queensland as local businesses started Christmas-related hiring, leading to a surge in retail and food service roles, the data showed.The education and cleaning and sanitation sectors also posted strong gains, but tech-related hiring continued to slow, with software development, data and analytics, and other tech roles seeing a modest decline in demand in recent months.But as labor market conditions typically respond to changes in economic activity with a lag, ANZ expects job ad volume to gradually decline as economic momentum softens and higher interest rates act as a restraint on demand.The Reserve Bank of Australia raised borrowing costs three times this year, but held the rate at 4.35% at its two most recent meetings in June and August. More hikes may be on the cards as policymakers remain concerned about upside risks to inflation, which remains above target.Australia's seasonally adjusted unemployment rate increased to 4.5% in July from 4.4% in the previous month as employment fell by 15,800 people, official Australian Bureau of Statistics data showed in August."While the ABS highlighted larger-than-usual uncertainty around the estimates, we continue to expect labor market conditions to ease and unemployment to drift higher gradually over the months ahead," said Jasmine Zheng, a senior economist at ANZ. But given the resilience of the ANZ-Indeed series, "we expect the rise in the unemployment rate to be modest," Zheng said.

ASX 200